Centre Hospitalier Le Mans

Le Mans, Pays de la Loire Region 72037

0 studies enrolling now · 7 studies all time

What they study most

ALK+ Advanced NSCLC, Adjuvant, Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation, EGFR, Early Stage Lung Cancer, Exon 20, Lung Cancer, Melanoma, NSCLC, Stage IB-IIIA, Post-essential Thrombocythemia Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-surgical

Studies at this site

• REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors) — Running, not enrolling
• A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection — Running, not enrolling
• A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension — Completed
• Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma — Running, not enrolling
• A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer — Completed
• A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) — Completed